OLD Mutual Customised Solutions Proprietary Ltd. grew its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 56.3% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 5,000 shares of the company’s stock after buying an additional 1,800 shares during the quarter. OLD Mutual Customised Solutions Proprietary Ltd.’s holdings in IDEXX Laboratories were worth $782,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds also recently made changes to their positions in IDXX. Atlantic Trust Group LLC purchased a new position in shares of IDEXX Laboratories in the 3rd quarter valued at about $65,381,000. Renaissance Technologies LLC lifted its stake in IDEXX Laboratories by 18.2% during the fourth quarter. Renaissance Technologies LLC now owns 1,879,804 shares of the company’s stock worth $293,964,000 after purchasing an additional 290,004 shares during the last quarter. Carillon Tower Advisers Inc. purchased a new stake in IDEXX Laboratories during the fourth quarter worth approximately $38,842,000. American Century Companies Inc. lifted its stake in IDEXX Laboratories by 32.3% during the fourth quarter. American Century Companies Inc. now owns 946,391 shares of the company’s stock worth $147,997,000 after purchasing an additional 231,216 shares during the last quarter. Finally, Wells Fargo & Company MN lifted its stake in IDEXX Laboratories by 57.8% during the fourth quarter. Wells Fargo & Company MN now owns 535,026 shares of the company’s stock worth $83,668,000 after purchasing an additional 196,058 shares during the last quarter. Institutional investors and hedge funds own 87.37% of the company’s stock.
Shares of IDEXX Laboratories, Inc. (IDXX) opened at $190.31 on Monday. The firm has a market capitalization of $16,580.34, a P/E ratio of 60.22, a P/E/G ratio of 2.33 and a beta of 0.58. IDEXX Laboratories, Inc. has a 52 week low of $146.09 and a 52 week high of $207.14. The company has a debt-to-equity ratio of -11.26, a quick ratio of 0.80 and a current ratio of 0.97.
In other news, Director Bruce L. Claflin acquired 1,000 shares of IDEXX Laboratories stock in a transaction on Wednesday, February 7th. The stock was bought at an average price of $179.58 per share, for a total transaction of $179,580.00. Following the completion of the purchase, the director now owns 1,000 shares in the company, valued at $179,580. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Brian P. Mckeon sold 6,602 shares of the business’s stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $181.36, for a total value of $1,197,338.72. Following the completion of the sale, the vice president now owns 47,040 shares of the company’s stock, valued at approximately $8,531,174.40. The disclosure for this sale can be found here. In the last quarter, insiders sold 91,736 shares of company stock valued at $16,193,502. 2.77% of the stock is owned by company insiders.
Several equities research analysts recently weighed in on IDXX shares. Bank of America boosted their target price on IDEXX Laboratories from $200.00 to $220.00 and gave the stock a “buy” rating in a research note on Friday, February 2nd. Canaccord Genuity restated a “buy” rating and set a $210.00 target price on shares of IDEXX Laboratories in a research note on Monday, January 29th. BidaskClub upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Tuesday, January 16th. Zacks Investment Research cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. Finally, Piper Jaffray started coverage on IDEXX Laboratories in a research note on Tuesday, January 16th. They set an “overweight” rating and a $200.00 target price for the company. One analyst has rated the stock with a sell rating, five have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $194.00.
COPYRIGHT VIOLATION NOTICE: This piece of content was posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3301742/old-mutual-customised-solutions-proprietary-ltd-buys-1800-shares-of-idexx-laboratories-inc-idxx.html.
IDEXX Laboratories Profile
IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.